According to the product label, alafacept (brand name, Amevive) is "an immunosuppressive dimeric fusion protein" that "interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction". All of which is interesting, but doesn't seem related to diabetes. It's given once weekly by intramuscular injection, and is approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis. Diabetes and related terms aren't mentioned in the label.
But it has been studied in diabetes — to be more specific, one study has been done, to see if alefacept might be able to stop or slow the progression of type 1 diabetes in newly-diagnosed patients. The study, "Inducing Remission in New-onset Type 1 Diabetes with Alefacept," has the acronym of "T1DAL," and has its own website at www.t1dal.org. I can't find the official meaning of the acronym, but presume the "T1D" stands for "Type 1 Diabetes" and the "AL" stands for "ALafacept."
The study's results have been published twice, first at the 12-month point, Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, pla